A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia

What is the purpose of this trial?

Brief Summary:

The purpose of this study is to determine whether add-on TAK-831 is superior to placebo on the Positive and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).


Participation Guidelines

Ages: 18 - 50 years

Gender: Both


Takeda Pharmaceuticals, America, Inc.

Start Date: 03/28/2018

End Date: 04/20/2020

Last Updated: 01/17/2019

Study HIC#: 2000022363

Get Involved

For more information about this study, contact:
Leigh Flynn
+1 203-974-7540
leigh.flynn@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image